Hannah Hosrom Campbell
Nurse Practitioner · Sebring, FLNPI 1558509612
Payments from drug & device makers
Across 532 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Bayer$1K
- Amgen$936
- Novo Nordisk$788
- Lilly USA, LLC$721
- Corcept Therapeutics$618
- plus $5K from 30 others
What the payments were for
- Travel & lodging$98310%
- Food & beverage$9,28390%
- Education$691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 32 | $1,486 |
| Bayer | 51 | $1,045 |
| Amgen(2 entities) | 58 | $936 |
| Novo Nordisk | 43 | $788 |
| Lilly USA, LLC | 50 | $721 |
| Corcept Therapeutics | 25 | $618 |
| Mannkind Corporation | 45 | $602 |
| Boehringer Ingelheim | 32 | $585 |
| Xeris Pharmaceuticals, Inc. | 22 | $443 |
| Sanofi-aventis U.S. LLC | 26 | $410 |
| Dexcom, Inc. | 19 | $391 |
| AstraZeneca | 24 | $361 |
| Fresenius USA Marketing, Inc. | 18 | $251 |
| Merck | 17 | $244 |
| Mallinckrodt Hospital Products Inc. | 12 | $242 |
| IBSA Pharma Inc. | 11 | $206 |
| Calliditas Therapeutics US Inc. | 7 | $155 |
| Tandem Diabetes Care, Inc. | 5 | $120 |
| Abbott | 5 | $106 |
| Ascendis Pharma Endocrinology Inc | 3 | $80 |
| Ascensia Diabetes Care US Inc. | 3 | $66 |
| Amneal Pharmaceuticals LLC | 3 | $59 |
| Alnylam Pharmaceuticals Inc. | 2 | $54 |
| Aurinia Pharma U.S., Inc. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Akebia Therapeutics Inc | 2 | $44 |
| Vifor Pharma, Inc. | 2 | $37 |
| Sanofi | 2 | $35 |
| Baxter Healthcare | 1 | $25 |
| AbbVie | 1 | $22 |
| GRT US Holding, Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $20 |
| Sequel Med Tech, LLC | 1 | $20 |
| Insulet Corporation | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Cequr Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$804
- Ozempic$125
- Korlym$125
How this compares
$10,334 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 442 | $624,306 |
| MounjaroTirzepatide | 450 | $575,631 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 287 | $300,912 |
| TrulicityDulaglutide | 231 | $279,440 |
| Tresiba Flextouch U-200Insulin Degludec | 170 | $182,012 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 134 | $145,774 |
| JardianceEmpagliflozin | 100 | $114,957 |
| FarxigaDapagliflozin Propanediol | 75 | $82,680 |
| Tresiba Flextouch U-100Insulin Degludec | 112 | $74,841 |
| RybelsusSemaglutide | 38 | $67,961 |
| Xigduo XrDapaglifloz Propaned/Metformin | 51 | $54,798 |
| JanuviaSitagliptin Phosphate | 46 | $51,883 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 25 | $39,720 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 43 | $31,182 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $29,684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $721 | $874,547740 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $788 | $738,570530 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $410 | $300,912287 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Tradjenta | $585 | $280,681252 claims |
| AstraZenecaFarxiga | $361 | $82,68075 claims |
| MerckJanuvia, Janumet Xr | $244 | $64,52258 claims |
| AbbVieSynthroid | $22 | $27,180291 claims |
| IBSA Pharma Inc.Tirosint, Tirosint-Sol | $206 | $14,14638 claims |
| BayerKerendia | $1,045 | $11,60612 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $59 | $5,430619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Sebring
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
- Maya BloombergMiami$202K
- Jennifer PuleoTampa$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.